Back to Search Results
Back to Results
Head and Neck
General Information
Study Name:
Safety evaluations of Nivolumab (anti-PD-1) added to Chemoradiotherapy (CRT) platforms in patients with intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma
Age Group:
Adult
Protocol Number:
NCT02764593
Background Information:
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Offered at:
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
Histologically or cytologically-confirmeNEKTARNd diagnosis of HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx.
Intermediate-risk group: Oropharynx cancer that is p16-positive by immunohistochemistry with smoking status > 10 Pack-years, stage T1-2N2b-N3 OR ≤ 10 pack-years, stage T4N0-N3 or T1-3N3.
Additional eligibility in protocol
Ineligibility Information
Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and neck tissue) metastatic disease.
Patients with oral cavity cancer are excluded from participation if resection of the primary tumor is considered technically feasible by an oral or head and neck cancers surgical subspecialist.
Additional ineligibility in protocol
Contact Information
Contact Name:
Kelly Jeffords, CCRP
Contact Phone:
571-472-0631
Contact Email:
kelly.jeffords@inova.org
Additional information can be found at
https://clinicaltrials.gov/ct2/show/NCT02764593